Lonza
Lonza is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in combination with Nivolumab and Lenvatinib compared to Double Placebo and Lenvatinib in Participants with Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) after Failure of First-Line Treatment that Included an Anti-PD-(L)1 Compound (GDFATHER-HCC-01)
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab plus Nivolumab with or without Docetaxel versus Docetaxel Monotherapy in Second-Line Treatment of Participants with Metastatic Non-Squamous Non-Small Cell Lung Cancer (GDFATHER-NSCLC-02)
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2a, Dose Escalation Study of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Sympomatic Despite Treatment with H1 Antihistamines and/or Omalizumab, or who Cannot Tolerate Omalizumab
Sponsor Jasper Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab versus Placebo, in Combination with Pembrolizumab, Pemetrexed, and Carboplatin, in First-Line Treatment of Participants with Metastatic Non-Squamous Non-Small Cell Lung Cancer (GDFATHER-NSCLC-01)
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, first-in-human, two-part, open-label clinical trial of intravenous administration of CTL-002 given as monotherapy and/or in combination with an anti-PD-1 checkpoint inhibitor in subjects with advanced-stage, relapsed/refractory solid tumors.
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
CLEAR-AKI: A multi-center, randomized, double blinded, placebo-controlled, four arm, parallel-group, dose-finding phase 2b study to investigate the safety and efficacy of TIN816 via a single intravenous infusion in the treatment of participants associated with sepsis- associated acute kidney injury (SA-AKI)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A multi-center, randomized, placebo- and active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment with H1-Antihistamines
Sponsor Jasper Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Lonza?
The 2026-10-09 snapshot links Lonza to 8 distinct CTIS trials. Recorded services include Laboratory services, Drug product Quality Control testing (release and stability), Drug Substance: Release testing (Polysorbate), Stability testing (Polysorbate), Medicinal product management, among 14 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Lonza?
The most frequently recorded therapeutic areas are Hepatology, Solid Tumor Oncology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Lonza conducted?
The linked trials record locations in 15 countries, including Germany, Spain, Italy, Bulgaria, France. These are trial locations, not confirmed office locations or countries where Lonza delivered services.
What can this page tell me about Lonza's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Lonza. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Lonza AG